S-3ASR ·Filed May 15, 2026

INSM

INSMED Inc
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001140361-26-021704
Notable filing: S-3ASR
Actionable Insight • Neutral

Monitor subsequent prospectus supplements for specific offering terms. The shelf itself is routine, but actual issuances could signal near-term dilution or debt financing. Given the strong recent earnings and BRINSUPRI launch, any equity offering would likely be viewed as opportunistic rather than desperate.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INSM ▲ +23.45% at T+60d
NEUTRAL call ✓ call won +23.45% · α vs SPY +18.60% · entry $107.15 → $132.28
Entry anchored
May 15, 03:59 PM ET
via exchange tick
T+1d
+0.24%
call +0.24% · α +0.89%
$107.41
settled 5mo ago
T+5d
+1.61%
call +1.61% · α -0.01%
$108.87
settled 4mo ago
T+20d
-10.85%
call -10.85% · α -12.44%
$95.52
settled 4mo ago
T+60d
+23.45%
call +23.45% · α +18.60%
$132.28
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Insmed filed an automatic shelf registration (S-3ASR) covering an indeterminate amount of common stock and debt securities. The filing provides maximum financial flexibility after reporting strong Q1 2026 results with revenue up 230% YoY and an EPS beat. No specific offering is announced, and the shelf is likely opportunistic rather than a distress-driven capital raise.

Key Facts

  • Registers common stock and debt securities in indeterminate amounts for continuous offering under Rule 415
  • Insmed qualifies as a well-known seasoned issuer, effective immediately upon filing
  • Proceeds to be used for working capital and general corporate purposes
  • Follows strong Q1 2026 earnings: revenue $306M (+230% YoY) and EPS beat of -$0.76 vs consensus -$0.90
  • Stock closed at $115.62 on May 14, 2026, with market cap of $25.1B

Financial Impact

Indeterminate amount; no offering size specified. Registration allows future issuances at undisclosed terms.

dilutiondebt

Risk Factors

  • Potential dilution from future common stock issuances
  • Increased leverage from debt securities offerings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (28 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001140361-26-021704
Document: ny20072736x1_ex25-1.htm0001140361-26-021704
Document: ny20072736x1_ex107.htm0001140361-26-021704
Document: ny20072736x1_ex5-2.htm0001140361-26-021704
Document: ny20072736x1_ex5-1.htm0001140361-26-021704
Document: ny20072736x1_ex23-1.htm0001140361-26-021704
Document: 0001140361-26-021704-index-headers.html0001140361-26-021704
Document: 0001140361-26-021704-index.html0001140361-26-021704
Document: 0001140361-26-021704.txt0001140361-26-021704
18 reports for INSM
Performance horizon
86% Hit rate 6 of 7 directional calls best @ T+60▲ +31.86%Mar 30, 2026
Filters
Rows
Reports for INSM — sortable, filterable
TypeNow
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 4/10
$130.66 $119.92▼ −8.22%▼ −6.70%$109.99 (−15.82%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$126.33 $129.41▲ +2.44%▲ +4.19%$109.99 (−12.93%)
Aug 6, 2026
8w ago
8-K
BULLISH ★ 8/10
$132.55 $126.68▼ −4.43%▼ −5.03%$109.99 (−17.02%)
Jul 24, 2026
10w ago
Institutional Cluster
NEUTRAL ★ 4/10
$106.92 $125.77▲ +17.63%▲ +14.00%$109.99 (+2.87%)
Jul 21, 2026
10w ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$108.62 $128.46▲ +18.27%▲ +15.70%$109.99 (+1.26%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$107.46 $126.33▲ +17.56%▲ +13.94%$109.99 (+2.35%)
Jun 26, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$104.74 $106.92▲ +2.08%▲ +2.36%$109.99 (+5.01%)
Jun 5, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$94.17 $111.54▲ +18.45%▲ +16.81%$109.99 (+16.80%)
Jun 5, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$94.17 $111.54▲ +18.45%▲ +16.81%$109.99 (+16.80%)
May 15, 2026
19w ago
S-3ASR
NEUTRAL ★ 3/10
$107.15 $95.52▼ −10.85%▼ −12.44%$109.99 (+2.65%)
Showing 10 of 18

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access